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Bone mineral density in HIV participants randomized to raltegravir and lopinavir/
ritonavir compared with standard second line therapy
Abstract
Objective: To compare changes over 48 weeks in bone mineral density (BMD) between participants
randomized to lopinavir/ritonavir (LPV/r) + raltegravir (RAL) or LPV/r + 2-3 nucleoside/nucleotide reverse
transcriptase inhibitors (N(t)RTIs) as second line therapy. Design: 48-week open-label sub-study of the
Second Line trial conducted in South Africa, India, Thailand, Malaysia and Argentina. Methods: Dual
energy X-ray absorptiometry scans of proximal femur and lumbar spine were performed at baseline and
week 48. Linear regression was used to compare means of differences between arms. McNemars test
compared osteopenia and osteoporosis. Associations between percentage BMD changes and baseline
variables were assessed by multivariate linear regression. Results
Results: Two hundred and ten participants
were randomized. Analyses were adjusted for sex, BMI and smoking status. Mean (95% CI) proximal
femur BMD% reduced over 48 weeks by -5.2% (-6.7 to -3.8%) in the LPV/r+2-3N(t)RTIs arm and by -2.9%
(-4.3 to -1.5%) in the LPV/r+RAL arm (P = 0.0001). Lumbar spine BMD reduced by -4.2% (-5.7 to -2.7%) in
the LPV/r+2-3N(t)RTIs arm and by -2.0% (-3.5 to -0.6%) in the LPV/r+RAL arm (P = 0.0006). The incidence
of osteopenia (7.6%) and osteoporosis (2.0%) assessed over 48 weeks were similar between arms.
Reduced BMD over 48 weeks was significantly associated with longer duration of tenofovir on study [%
change (SE) -1.58 (0.38) femur, -1.65 (0.38) spine, P = 0.0001] and low baseline BMI [% change (SE) 0.5
(0.13) femur, 0.17 (0.07) spine; P < 0.01]. Conclusion
Conclusion: An N(t)RTI-sparing antiretroviral regimen of LPV/r
and raltegravir as second line therapy is associated with less bone loss than a LPV/r regimen containing
N(t)RTIs.
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Bone mineral density in HIV participants randomized
to raltegravir and lopinavir/ritonavir compared with
standard second line therapy
Allison Martina, Cecilia Moorea, Patrick W.G. Mallonb, Jennifer Hoyc,
Sean Emerya, Waldo Bellosod, Praphan Phanuphake, Samuel Ferretf,
David A. Coopera, Mark A. Boyda, on behalf of the
Second Line study team
Objective: To compare changes over 48 weeks in bone mineral density (BMD) between
participants randomized to lopinavir/ritonavir (LPV/r) þ raltegravir (RAL) or LPV/r þ 2–
3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTIs) as second line therapy.
Design: 48-week open-label sub-study of the Second Line trial conducted in
South Africa, India, Thailand, Malaysia and Argentina.
Methods: Dual energy X-ray absorptiometry scans of proximal femur and lumbar spine
were performed at baseline and week 48. Linear regression was used to compare means
of differences between arms. McNemars test compared osteopenia and osteoporosis.
Associations between percentage BMD changes and baseline variables were assessed
by multivariate linear regression.
Results: Two hundred and ten participants were randomized. Analyses were adjusted
for sex, BMI and smoking status. Mean (95% CI) proximal femur BMD% reduced over
48 weeks by 5.2% (6.7 to 3.8%) in the LPV/rþ2-3N(t)RTIs arm and by 2.9%
(4.3 to 1.5%) in the LPV/rþRAL arm (P ¼ 0.0001). Lumbar spine BMD reduced by
4.2% (5.7 to 2.7%) in the LPV/rþ2-3N(t)RTIs arm and by 2.0% (3.5 to 0.6%)
in the LPV/rþRAL arm (P ¼ 0.0006). The incidence of osteopenia (7.6%) and osteoporosis (2.0%) assessed over 48 weeks were similar between arms. Reduced BMD
over 48 weeks was significantly associated with longer duration of tenofovir on study
[% change (SE) 1.58 (0.38) femur, 1.65 (0.38) spine, P ¼ 0.0001] and low baseline
BMI [% change (SE) 0.5 (0.13) femur, 0.17 (0.07) spine; P < 0.01].
Conclusion: An N(t)RTI-sparing antiretroviral regimen of LPV/r and raltegravir as
second line therapy is associated with less bone loss than a LPV/r regimen containing
ß 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
N(t)RTIs.
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Introduction
Continued morbidity from non-AIDS illnesses is a
concern in the management of HIV-infected patients

despite the success in controlling virus replication.
Low bone mineral density (BMD) and osteoporosis
are prevalent in HIV-infected patients with some evidence suggesting that more osteoporosis-related fractures
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may be experienced in HIV-infected patients than
the general population [1,2]. Osteopenia occurs in up
to 50% of HIV patients and osteoporosis up to 15% [3].
Cross-sectional studies suggest this prevalence is associated with both HIV infection itself and a greater
prevalence of traditional risk factors for low BMD; such
as smoking, low BMI and steroid use [1]. However,
studies in combination antiretroviral treatment (cART)
naive patients initiating therapy have demonstrated loss of
BMD over the first 48–96 weeks of treatment [4–8],
with greater loss experienced by those initiating
nucleoside/nucleotide reverse transcriptase inhibitors
(N(t)RTIs) [5,6], most notably with tenofovir (TDF)
[9]. In fact reduced BMD appears to be one of the few
toxicities that worsens with cART treatment [10]. In an
evaluation of 4640 HIV participants in 26 randomized
ACTG trials the incidence of fractures was higher in the
first 2 years after cART initiation than in subsequent years
[11]. Little is known about the effects of exposure to HIV
integrase inhibitors and BMD. There is some evidence
that raltegravir (RAL) may increase BMD in the hip
and spine over 48 weeks compared with TDF [12] or
protease inhibitors [13]. However, these two studies were
conducted on a small number of participants (n ¼ 37 and
74, respectively) and only one was a randomized study
[13].
The Second Line study provided a unique opportunity to
examine if a N(t)RTI-sparing cART regimen containing
RAL and lopinavir/ritonavir (LPV/r) results in less
BMD loss than combinations containing N(t)RTIs in
HIV-infected patients.

Methods
The Second Line study is a 96-week, multinational
trial of participants virologically failing first-line therapy
randomized 1 : 1 to currently recommended second line
treatment (2-3N(t)RTI þ LPV/r) or RAL (400 mg b.i.d.)
þ LPV/r (400/100 mg b.i.d. or 800 mg/200 mg q.i.d.).
Eligible participants were HIV-1 positive adults
(aged 16 years) who had received first-line cART
comprised of a nonnucloeside reverse transcriptase
inhibitor (NNRTI)þ2N(t)RTIs for at least 24 weeks
with no change within 12 weeks prior to screening;
evidence of virological failure defined by two consecutive
(7 days apart) plasma HIV RNA viral load more than
500 copies per ml; no previous exposure to protease
inhibitors and/or integrase inhibitors. The study was
approved by each site’s Ethics Committee and was
registered at Clinicaltrials.gov (NCT00931463). The
cohort median (IQR) age was 38.5 (32.4–44.4) years,
55% male, 42% Asian and 36% African, 73% heterosexual
transmission, with an estimated median duration of HIV
infection of six (3.6–8.7) years. The primary 48-week
results of the Second Line study have been described [14].

Of the 37 sites that participated in the Second Line
study eight sites from five countries (South Africa, India,
Malaysia, Thailand and Argentina) participated in the
body composition sub-study (clinicaltrials.gov identifier:
NCT01513122). These sites had access to a dual energy
X-ray absorptiometry (DXA) scanner and recruitment was
open to all participants screened at these sites between July
2010 and July 2011. The sub-study was approved by each
site’s Ethics committee’s and all participants gave written,
informed consent. DXA scans were performed at baseline
and week 48 on either Lunar (India n ¼ 48, Malaysia
n ¼ 13, Argentina n ¼ 8, Thailand n ¼ 22) or Hologic
(Thailand n ¼ 26, South Africa n ¼ 94) DXA scanners. To
assess BMD the proximal femur and lumbar spine (L2-L4)
were measured as per a standard protocol provided to
all sites. We did not use phantoms for quality assurance
and scans were not subjected to central interpretation.
The primary objective was to determine the treatment
arm difference in mean change from baseline BMD (%)
at the proximal femur and lumbar spine to 48 weeks.
We hypothesized that participants randomized to LPV/
rþRAL would demonstrate smaller reductions in BMD
over the 48 weeks compared with LPV/rþ2-3N(t)RTIs.
The secondary objectives included comparison between
treatment arms for percentage of participants with
osteopenia (T-score between 1.0 and 2.5) and
osteoporosis (T-score less than 2.5), mean percentage
change from baseline in Z-score and T-score, and
to explore the relationship between lumbar spine and
proximal femur BMD and baseline clinical demographics
and cART. The T-score is the number of SDs below
the average for a young adult at peak bone density. The
Z-score is the number of SDs below an average person of
the same age.
The baseline covariates that were included in the
multivariate model as predictors of percentage change
in proximal femur and lumbar spine BMD were age, sex,
ethnicity, BMI, smoking, blood pressure; HIV and ART
markers (randomized treatment arm, CD4þ lymphocyte
counts, plasma HIVRNA, prior and on-study use of
TDF, duration of TDF use); body composition (total
body fat and lean mass); and bone-specific variables (prior
hypogonadism and physical activity).

Statistical analysis
Analyses included available data from all participants who
consented to the sub-study, who underwent randomization, received at least one dose of study medication and
who completed both a week 0 and 48 DXA scan. Results
were considered statistically significant at a two-sided
a ¼ 0.05. A sample size of 100 per randomized treatment
arm was required to achieve 80% power to detect a mean
difference of 1.7% change in BMD.
Linear regression was used to compare means of
differences (baseline to week 48) between randomized
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arms. McNemars test for paired proportions was used to
compare the categorized BMD variables. The association
between BMD changes and the baseline variables was
assessed by linear regression, any variable with P < 0.1 in
univariate was included in the multivariate model.
Backward stepwise methods were used to build the
multivariate model. If parameters were found to be not
normally distributed then the equivalent nonparametric
test was used.

Results
The patient disposition is outlined in Figure 1. Six
hundred and ninety-nine participants were screened
for the parent Second Line study, of whom 236 consented
to the bone sub-study. Two hundred and eleven participants were eligible and randomized into the sub-study
and 210 made up the analysis population. Ninety-seven
participants reached week 48 in the r/LPVþ2-3N(t)RTI
arm and 107 in the r/LPVþRAL arm.
The baseline characteristics of the sub-study cohort are
described in Table 1. The median age of the sub-study
cohort was 38.8 years, 48% were male, 51% were Asian
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and 43% were African. Participant’s median duration
on cART at randomiszation was 3.4 years, 34% were
on zidovudine, 48% on stavudine and 17% on TDF at
baseline. The prevalence of osteopenia at the proximal
femur was 20% and osteoporosis 2%, whereas at the
lumbar spine prevalence of osteopenia was 31% and
osteoporosis was 5%. At baseline, there were imbalances
between the two treatment arms for sex, BMI and
smoking status. All analyses were adjusted for the
imbalances in these covariates.
The primary endpoint is outlined in Figure 2. The mean
(95% CI) proximal femur BMD (%) significantly
reduced over the 48 weeks by 5.2% (6.7 to
3.8%) in the LPV/rþ2-3N(t)RTIs arm and by
2.9% (4.3 to 1.5%) in the LPV/rþRAL arm, with
a mean difference of 2.4% (3.5 to 1.2; P ¼ 0.0001).
The mean (95% CI) lumbar spine BMD (%) significantly
reduced by 4.2% (5.7 to 2.7%) in the LPV/rþ
2-3N(t)RTIs arm and by 2.0% (3.5 to – 0.6%) in the
LPV/rþRAL arm, with a mean difference of 2.1%
(3.3 to 0.9; P ¼ 0.0006). These results demonstrate
that across two different anatomical regions BMD
reduced in both treatment arms over 48 weeks, but
reduced significantly less in recipients of r/LPVþRAL
compared with r/LPVþ2-3N(t)tRTI arm.

Screened (n = 699)

Consented to sub-study
(n = 236)

25 subjects not randomized
Ineligible (n = 17)
Withdrawn (n = 6)
Other:
Death (n = 1)
Lost to follow-up (n = 1)

Randomized (n = 211)

Exited before analysis, never
received study therapy (n = 1)

Analysis population (n = 210)

r/LPV + 2-3N(t)RTI (n = 102)

r/LPV + RAL (n = 108)

Lost to follow-up
(n = 1)

Deaths (n = 1)

Deaths (n = 4)

Reached week 48 (n = 97)

Reached week 48 (n = 107)

Fig. 1. Patient disposition of Second Line bone sub-study.
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Table 1. Baseline characteristics.

Age (years)
Sex, male
Ethnicity
Caucasian
Asian
Hispanic
African
Unknown
BMI
<18.5
18.5 to <20
20 to <30
30 to <35
35
HIV RNA log (copies/ml)
CD4þ T lymphocytes (cells/ml)
Hepatitis C antibody (positive)
Hip/waist ratio
Lumbar spine BMD (g/cm2)
TDF prior to study
No TDF prior to study
Lumbar spine T score
Lumbar spine Z score
Proximal femur BMD (g/cm2)
Proximal femur T score
Proximal femur Z score
Proximal femur osteopenia
Proximal femur osteoporosis
Lumbar spine osteopenia
Lumbar spine osteoporosis
Smoking
Current
Recently (within 12 months)
Past
Never
Alcohol consumption
0–2 drinks per day
2 drinks per day
Days of exercise
Brisk walk past 7days
Moderate activity past 7 days
Vigorous activity past 7 days
History of diabetes (yes)
Family history of diabetes (yes)
History nontraumatic fractures (yes)
Parental history of hip fracture (yes)
cART duration
On TDF (yes)
On d4T (yes)
On ZDV (yes)

r/LPVþ 2-3N(t)RTI (n ¼ 102)

r/LPV þ RAL (n ¼ 108)

Total (n ¼ 210)

38.6 (34.2–44.1)
55 (53.9)

38.9 (32.6–44.4)
45 (41.7)

38.8 (32.9–44.2)
100 (47.6)

4
53
1
44

(3.9)
(52.0)
(1.0)
(43.1)
0

18 (17.6)
48 (47.1)
26 (25.5)
7 (6.9)
3 (2.9)
4.3 (3.8–4.9)
185 (80–296)
4 (3.9)
1.2 (1.1–1.2)
1.1 (0.9–1.2)
1.0 (1.0–1.0)
1.1 (0.9–1.2)
0.7 (1.5–0.1)
0.6 (1.3–0.2)
1.0 (0.9–1.1)
0.3 (0.8–0.4)
0.2 (0.6–0.7)
18 (19.4)
0 (0.0)
34 (36.6)
5 (5.4)
22
1
16
63

(21.6)
(1.0)
(15.7)
(61.8)

3
55
2
47
1

(2.8)
(50.9)
(1.9)
(43.5)
(0.9)

13 (12.0)
59 (54.6)
24 (22.2)
8 (7.4)
4 (3.7)
4.1 (3.4–4.6)
218 (117–315)
5 (4.6)
1.1 (1.1–1.2)
1.0 (1.0–1.2)
1.0 (0.9–1.2)
1.1 (1.0–1.2)
0.7 (1.4–0.2)
0.5 (1.4–0.2)
0.9 (0.9–1.0)
0.3 (1.0–0.6)
0.1 (0.8–0.7)
21 (20.0)
3 (2.9)
28 (26.7)
5 (4.8)
14
2
16
76

7 (3.3)
108 (51.4)
3 (1.4)
91 (43.3)
1 (0.5))
31 (14.8)
107 (51.0)
50 (23.8)
15 (7.1)
7 (3.3)
4.1 (3.5–4.7)
202 (104–307)
9 (4.3)
1.2 (1.1–1.2)
1.1 (1.0–1.2)
1.0 (1.0–1.2)
1.1 (1.0–1.2)
0.7 (1.5–0.2)
0.5 (1.4–0.2)
1.0 (0.9–1.0)
0.3 (0.9–0.5)
0.1 (0.7–0.7)
39 (19.7)
3 (1.5)
62 (31.3)
10 (5.0)

(13.0)
(1.9)
(14.8)
(70.4)

36 (17.1)
3 (1.4)
32 (15.2)
139 (66.2)

97 (95.1)
5 (4.9)

104 (96.3)
4 (3.7)

201 (95.7)
9 (4.3)

5.0 (3.0–7.0)
3.0 (1.0–6.0)
1.0 (0.0–3.0)
1 (1.0)
20 (19.6)
3 (2.9)
2 (2.0)
2.9 (1.8–5.9)
20 (19.6)
50 (49.0)
32 (31.4)

7.0 (5.0–7.0)
3.0 (0.0–5.0)
1.0 (0.0–2.0)
3 (2.8)
25 (23.1)
0
2 (1.9)
3.7 (2.1–6.0)
16 (14.8)
51 (47.2)
40 (37.0)

6.0 (3.0–7.0)
3.0 (0.0–5.0)
1.0 (0.0–2.0)
4 (1.9)
45 (21.4)
3 (1.4)
4 (1.9)
3.4 (2.0–6.0)
36 (17.1)
101 (48.1)
72 (34.3)

Data are median (IQR) or n (%). BMD, bone mineral density; cART, combined antiretroviral therapy; d4T, stavudine; N(t)RTI, nucleoside/
nucleotide reverse transcriptase inhibitor; r/LPV, ritonavir-boosted lopinavir; RAL, raltegravir; TDF, tenofovir; ZDV, zidovudine.

The change over 48 weeks in T and Z scores at both the
proximal femur and lumbar spine were significantly
different between the two treatment arms. The mean
difference (r/LPVþ2-3N(t)RTIs versus r/LPVþRAL) in
proximal femur for Z score was 0.18 (0.3 to 0.19,
P ¼ 0.003) and for T score was 0.20 (0.3 to 0.1,
P ¼ 0.0002). The mean difference (r/LPVþ23N(t)tRTIs versus r/LPVþRAL) in lumbar spine femur
for Z score was 0.18 (0.3 to 0.1, P ¼ 0.006) and for
T score was 0.21 (0.3 to 0.1, P ¼ 0.0001). These
results confirm the hypothesis that BMD reduction was

less in the r/LPVþRAL arm compared with r/LPVþ23NtRTI arm.
The prevalence of osteopenia (2.5 <T score<1.0) at
baseline in both treatment groups was 26% across the two
anatomical regions and the prevalence of osteoporosis
(T score  2.5) was 3%. The incidence of low BMD
(Z score < 2), osteopenia and osteoporosis at week
48 was not different between the two treatment arms
(Table 2). Only two (1%) participants experienced a bone
fracture, one in the N(t)RTI arm and one in the RAL arm.
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Proximal femur

Lumbar spine

0
–1
–2
r/LPV+2–3NtRTI

–3

r/LPV+RAL

–4
–5
–6

Fig. 2. Mean percentage change (SE) from week 0 to 48 in
proximal femur and lumbar spine bone mineral density
(BMD) by treatment arm.

The multivariate regression analysis results are
summarized in Table 3. The covariates that predicted a
change in BMD in both the lumbar spine and proximal
femur were higher baseline BMI and longer duration of
TDF on study. Having a higher baseline BMI predicted a
greater BMD at week 48, for every 1 kg/m2 increase
in BMI the femur BMD increased by 0.5% and spine
BMD by 0.17% (P < 0.01). Participants prescribed TDF
for longer throughout the 48 weeks of the study had
reduced BMD at week 48, for every 1 year of TDF use on
study the femur BMD reduced by 1.58% and spine
BMD by 1.65% (P ¼ 0.001).

Discussion
The effects of raltegravir on BMD in people living with
HIV have not been well defined. The bone sub-study
of the Second Line clinical trial was conducted on

2407

210 HIV-positive participants recruited from a range of
middle-income countries in which there is a paucity
of BMD data. The data generated in this sub-study of
participants with confirmed virological failure of an
NNRTIþ2N(t)RTI cART regimen, demonstrate that
effective second line therapy with either WHO standard
of care [ritonavir-boosted protease inhibitor (r/PI) þ 2-3
N(t)RTIs] or the nucleoside sparing regimen (r/LPV þ
RAL) reduced BMD over 48 weeks. However, the
raltegravir arm was associated with less BMD loss than the
N(t)RTI arm. The covariates predicting a greater loss of
BMD in both the lumbar spine and proximal femur
over the 48 weeks were low baseline BMI and longer
duration of TDF on study. In our regression analyses,
we were unable to detect an independent contribution
from treatment arm on BMD change. As such, use of
raltegravir provides an option to avoid the demonstrated
risks to bone health arising from use of tenofovir.
These findings are important as the use of integrase
inhibitors and tenofovir are becoming more common in
middle to low-income countries.
Previous studies examining the effect of raltegravir on
bone metabolism are limited. The SPIRAL-LIP study
was a small study conducted on 74 virologically
controlled participants randomized to either continue
with their r/PI regimen (n ¼ 35) or switch their r/PI to
raltegravir (n ¼ 39) while continuing their N(t)RTIs [13].
After 48 weeks, they reported no change in BMD or
T scores in the r/PI arm but a significant improvement in
total BMD, hip BMD and hip T score, with a significant
difference between treatment groups. The SPIRAL-LIP
study did not demonstrate any relationship between
TDF use and changes in BMD or T score [13]. Another
smaller, nonrandomized study [12] confirmed these
findings in a cohort of HIV-controlled osteopenic or
osteoporotic HIV participants (n ¼ 37) that switched

Table 2. Low bone mineral density, osteopenia, and osteoporosis.
N

Odds ratio (95% CI)a

P-value

2 (2.1)
1 (0.9)

0.47 (0.04, 5.7)

0.5507

3 (3.2)
9 (8.4)

2.8 (0.7, 10.7)

0.1442

7 (7.5)
8 (7.6)

1.1 (0.4, 3.2)

0.8619

8 (8.6)
8 (7.6)

0.8 (0.3, 2.2)

0.6487

3 (3.2)
1 (1.0)

0.4 (0.03, 4.3)

0.4259

5 (5.4)
4 (3.8)

0.8 (0.2, 3.2)

0.7215

New cases at week 48 n (%)

Low proximal femur BMD (Z score < 2)
LPV/r þ 2–3N(t)RTI
94
r/LPV þ RAL
106
Low lumbar spine BMD (Z score <2)
LPV/r þ 2-3N(t)RTI
94
r/LPV þ RAL
107
Proximal femur osteopenia (T score between 1 and 2.5)
LPV/r þ 2-3N(t)RTI
93
r/LPV þ RAL
105
Lumbar spine osteopenia (T score between 1 and 2.5)
LPV/r þ 2-3N(t)RTI
93
r/LPV þ RAL
105
Proximal femur osteoporosis (T score <–2.5)
LPV/r þ 2-3N(t)RTI
93
r/LPV þ RAL
105
Lumbar spine osteoporosis (T scoe <–2.5)
LPV/r þ 2-3N(t)RTI
93
r/LPV þ RAL
105

a
Adjusted for baseline imbalances in sex, BMI and smoking; BMD, bone mineral density; N(t)RTI, nucleoside/nucleotide reverse transcriptase
inhibitor; r/LPV, ritonavir boosted lopinavir; RAL, raltegravir.
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60
49
57
26
9
201
201
200

3.06 (2.61)
(8.2, 2.1)
0.36
0.71 (3.01)
(4.7, 0.4)
0.81
0.92 (1.83)
(3.8, 0.2)
0.62
0.09
Not included in multivariate as univariate >0.1
1.58 (0.38)
(2.3, 0.8)
0.0001
0.0001
0.00 (0.00)
(0.0, 0.)
0.62
0.62

34
3
32
132
201
198
201

0.36
0.81
0.62
0.0001

0.18 (0.07)
0.04 (0.06)
0.42 (0.16)

(0.3, 0.03)
(0.1, 0.2)
(0.7, 0.1)

0.02
0.57
0.01

Not included in multivariate as univariate >0.1

(5.3, 1.9)
(6.7, 5.2)
(4.5, 2.7)
(0.3, 0.8)

0.02
0.57
0.01

0.66
0.0001

0.48

(1.82)
(3.01)
(1.83)
(0.13)

0.48

1.67
0.71
0.92
0.50

(1.0, 2.2)

6
103
3
88
201

0.54
0.34

Overall
P-value

0.58 (0.82)

0.54
0.34

Pr> t

94
107

(3.1, 1.6)
(0.1, 0.0)

95% CI

0.74 (1.21)
0.04 (0.04)

% Change in
BMD (SE)

94
107
201

N

(1.85)
(3.05)
(1.85)
(0.07)

(6.8,
(1.9,
(6.3,
(0.0,

0.5)
10.1)
1.0)
0.3)

(2.3, 0.7)

(2.9, 1.8)
(0.1, 0.1)

95% CI

(1.46)
(1.47)
(1.46)
(1.57)

(7.6,
(7.7,
(6.5,
(6.6,

1.5)
1.9)
0.7)
0.4)

0.0031
0.0014
0.0149
0.0254

0.69
0.09
0.45
0.66
0.0001
>0.1

0.09
0.18
0.45
0.01

0.27

0.63
0.66

Pr> t

0.31
0.66
0.0001

0.01
0.01

0.27

0.63
0.66

Overall
P-value

0.0230
0.10 (0.07)
(0.2, 0.04)
0.16
0.16
Not included in multivariate as univariate >0.1
Not included in multivariate as univariate >0.1

4.39
4.77
3.00
3.53

1.05 (2.59)
(4.1, 6.2)
1.90 (1.10)
(4.1, 0.3)
0.68 (0.90)
(2.5, 1.1)
0.33 (0.74)
(1.1, 1.8)
1.65 (0.38)
(2.4, 0.9)
Not included in multivariate as univariate

3.13
4.09
2.65
0.17

0.82 (0.75)

0.58 (1.18)
0.02 (0.04)

% Change in
BMD (SE)

a
Reference group; % Change in BMD (SE): probability (standard error) co-efficient; r/LPV: ritonavir boosted lopinavir; N(t)RTI: nucleoside/nucleotide reverse transcriptase inhibitor; RAL: raltegravir;
TDF: tenofovir.

Randomization arm
r/LPV þ 2-3N(t)RTIa
r/LPV þ RAL
Age
Sex
Malea
Female
Race
Caucasiana
Asian
Hispanic
African heritage
BMI (kg/m2)
Smoking
Currentlya
Recently
Past
Never
Duration TDF prior to study (years)
Duration TDF on study (years)
CD4þ lymphocytes (cells/ml)
CD4þ nadir (cells/ml)
<50
50–99
100–199
200–299
300a
Total body fat (kg)
Total lean mass (kg)
Vigorous physical activity (days)

Risk Factor (n ¼ 201)

Lumbar spine

AIDS

Proximal femur

Table 3. Baseline predictors of percentage change in bone mineral density over 48 weeks included in the multivariate regression model.
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from TDFþr/PI to RALþr/PI. After 48 weeks, this
cohort experienced a significant increase in spine and hip
BMD as well as a significant reduction in bone turnover
markers [12]. One final small nonrandomized study
on 30 HIV, treatment-naive African–Americans given
RAL þ TDF/FTC for 2 years demonstrated a significant
reduction in total BMD of the same magnitude
demonstrated in the 1 year of this Second Line substudy (0.02 g/cm2) [15].
A reduction of between 0.02 and 0.05 g/cm2 or 2–5%
BMD over 48 weeks in lumbar spine and proximal femur
in this cohort is larger than previously reported cARTexperienced cohorts. Over 48 weeks in the STEAL study
a reduction of 0.01 g/cm2 BMD at the lumbar spine
and proximal femur was reported [16], in participants
who were virologically controlled but switched to either
abacavir/lamivudine or tenofovir/emtricitabine at baseline. In addition the SMART study reported a 0.8% loss
of femur BMD and 0.4% loss of spine BMD per year in
participants continuously ART treated and the majority
were virologically controlled at baseline [10]. Interestingly, the duration of cART at baseline in the STEAL
study and SMART study was greater compared with the
Second Line study, 6 years duration in STEAL and
SMART compared with 4 years (median 3.4) second line.
Therefore, in our Second Line study, the virologically
failing participants experienced an overall decrease in
BMD twice as great as other cART-experienced cohorts.
Whether or not this is due to virological control at
baseline is unknown. Interestingly, changing treatment in
virologically failing HIV patients appears to have similar
magnitudes of BMD loss as initiating treatment in naive
patients [15]. Long-term follow-up of the Second Line
study would be required to examine the magnitude of
BMD change further, however these data suggest that if
you continue N(t)RTIs into second line cART then you
are likely to see continuing bone mineral loss.
Evidence suggests that the prevalence of osteoporosis in
HIV-infected individuals may be more than three times
greater compared with HIV-uninfected controls [3].
The prevalence of osteoporosis in HIV has been reported
to be between 3 and 21% [17–19]. Osteopenia is
more common, affecting about 30–50% of HIV-positive
individuals [20,21]. Our data support these previous
estimates of bone disease in HIV populations, 20–31%
osteopenia and 2–5% osteoporosis at baseline. This
demonstrates that in middle-income countries where
treatment options are limited, similar rates of bone
disease are found compared with HIV populations
from developed countries. The reason for such a high
prevalence of bone disease in HIV is of concern and most
probably multifactorial. The influence of HIV disease,
social factors and cART all contribute. Studies have
confirmed that BMD is significantly lower in HIV
positive patients over a 1-year period compared with
HIV-negative patients, independent of cART [22],
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though in our multivariate analysis neither HIV duration
or HIV disease category were significant predictors of
low BMD. In addition, smoking and alcohol intake are
known lifestyle factors more common in the HIVinfected population and have previously been documented as associated with reduced BMD [1]. However,
in the Second Line study cohort neither smoking nor
alcohol was significant predictor of low BMD in the
multivariate regression analysis. Another lifestyle factor
known to affect BMD is a low BMI. In this analysis a low
BMI at baseline was associated with a low BMD over
48 weeks, which has been demonstrated previously
[23–25]. Ultimately, these differences in BMD did not
significantly affect clinically significant bone disease in
this cohort as only two participants experienced fractures.
The reason for this may be the relatively short time
frame of 48 weeks. A reduction in BMD would precede
the event of a fracture, and therefore longer term followup may be required.
Previous studies have demonstrated bone loss being
greater during the first year of treatment with TDFcontaining regimens compared with abacavir-containing
regimens [5,26–28]. To support these findings, evidence
of greater bone turnover has been reported in TDF
regimens [16,27,29]. Cumulative exposure to TDF has
also been shown to predict increased risk of osteoporotic
fracture [30]. Our finding that TDF was associated with
lower BMD outcomes over 48 weeks support these
previous data. Mechanisms for drug-induced bone
loss are not fully elucidated but likely are multifactorial.
One explanation for the affect of TDF on bone is via
bone remodelling by renal mechanisms with a resultant
loss of phosphorus [31]. Other cART implicated
with greater bone loss are protease inhibitors [4] and
thymidine analogues [6]; however, both these studies
were conducted on very small cohorts.
Fewer studies have looked at rates of actual bone fracture
among people with HIV. Between the years 2000 and
2008, 4% of HIV-positive patients in the United States
HIV Outpatient Study experienced bone fractures; a
significantly higher rate than that estimated in the general
US population [32]. Another study reported the relative
risk of fracture to be 2.87 per 100 persons in a HIV
population compared with 1.77 in non-HIV persons in a
study on more than 8000 HIV-infected patients and
2 million non-HIV-infected patients [33]. A metaanalysis of 26 randomized clinical trials including
4640 HIV-positive participants reported a fracture rate
of 0.4/100 person-years [11], and in a multivariate
analysis of their antiretroviral naive participants they
reported an increase in fracture associated with smoking
and glucocorticoids use, but not exposure to ART [11].
In this Second Line sub-study, only two participants (1%)
experienced a bone fracture over the 48 weeks of followup (one participant in the LPV/rþ2-3N(t)RTIs arm and
one in the LPV/rþRAL arm). This lower proportion of
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fractures could be explained by the relatively short
duration of the study and smaller number compared with
the previous reported cohorts. Longer term follow-up of
the Second Line study will provide greater clarification of
clinical bone disease in this cohort.
The measurement of BMD is not routine in middle to
low-income settings due to high cost. Therefore the
data available on the incidence and prevalence of clinical
bone disease in HIV in these populations is very limited.
The Second Line bone sub-study was conducted largely
in Asian [51%] (India, Thailand and Malaysia) and
African [43%] (South Africa) populations. There has only
been one previous cross-sectional study of BMD in
HIV-infected participants in India that demonstrated
cART and low BMI were associated with a lower BMD
[34]. One other study conducted bi-annual DXA scans in
a cohort of 500 sero-negative participants in Peru,
Thailand, San Francisco and South Africa and Brazil
treated with TDF/FTC and reported BMD loss at the
hip and spine with a TDF-containing regimen and 1%
population with fractures over 72 weeks [35]. Overall, the
data reported in this sub-study cohort are consistent with
the limited data previously presented in similar populations. In addition, the data in these middle-income HIV
populations are similar to that reported in developed
countries. What is novel is that the incidence of newly
acquired bone disease over a 48-week period has never
previously been reported. In this Second Line cohort the
incidence of up to 9% of newly identified cases of
osteopenia and osteoporosis over such a short period is a
concern among a relatively young population.
In this unique HIV population, osteopenia and
osteoporosis were common. The loss of BMD was less
in participants treated with raltegravir and greater in those
exposed to tenofovir throughout the study. These data
confirm that bone disease is a significant comorbidity in
the ongoing long-term management of HIV in middleincome countries.
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